Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18lk0201048)
Received: 23 October 2018
Accepted: 18 January 2019
First Online: 26 January 2019
Ethics approval and consent to participate
: This study was approved by the institutional review boards of each participating institution (Tokyo Medical and Dental University, National Cancer Center Hospital, and Kyoto Prefectural University of Medicine). Written, informed consent is to be obtained from patients and/or their representatives.
: Not applicable.
: The authors declare that they have no competing interests. Although AstraZeneca provided Olaparib as a gift, AstraZeneca does not play in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. All authors are not affiliated with AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.